Table 3. Prevalence of monotherapy and combined use of benzodiazepines in the previous 12 months in the general population by sex. São Paulo Megacity Mental Health Survey (N=2935).
| N (%) | SE | OR (95% CI) female/male | X2 | p-value | |
|---|---|---|---|---|---|
| Benzodiazepinesa | 162 (3.6) | 0.5 | 3.7 (2.0-6.7) | 18.2 | <0.0001 |
| Monotherapyb | 65 (1.8) | 0.4 | 3.6 (2.0-6.5) | 18.5 | <0.0001 |
| Combined usec | |||||
| Benzodiazepines +antidepressant | 79 (1.4) | 0.2 | 6.2 (2.3-16.7) | 13.3 | 0.0003 |
| Benzodiazepines + antipsychotics | 11 (0.2) | 0.1 | 11.3 (2.7-48.0) | 10.9 | 0.001 |
| Benzodiazepines + mood stabilizer | 20 (0.4) | 0.1 | 1.5 (0.5-5.2) | 0.5 | 0.4904 |
Weighted proportions. OR, odds ratio; CI, confidence interval. aAt least one psychotropic drug. bOnly benzodiazepines. cAny benzodiazepine drug plus another psychiatric medication. Sex comparison: males were used as the reference group.